Clinical Trials Directory

We are doing this study is to evaluate the outcomes of medial patellofemoral ligament (MPFL) reconstruction surgery. This surgery is a common treatment for recurrent patellofemoral instability. We want to find out what factors most influence the likelihood of this procedure being successful.

We are doing this study to find out if an experimental drug called KTX-1001 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and dosing schedule of the study drug for patients with multiple myeloma.

We are doing this study to compare a ketogenic diet (a diet with high fat, moderate protein, very low carbohydrate) versus a normal diet. We want to find out if it has any effect on survival time for people with glioblastoma multiforme (GBM). We also want to know how biomarkers change when people follow a ketogenic diet. A biomarker is a biological molecule found in blood, other body fluids, or tissues. Biomarkers may be a sign of a condition or disease and can be used to predict someone's response to a specific treatment.

We are doing this study to learn more about what causes glioblastoma (GBM), a type of brain cancer, and the factors that affect GBM patients' quality of life. This research will help us to understand why some people get GBM, including how their genes and health history may contribute to tumor development and progression.

Some kids need a special tube called a central line to get medicine and food. But when the tube isn’t being used, it can get blocked or infected. To help stop this, doctors use a liquid called a locking solution. In this study, kids will be randomly placed into one of two groups: - Group 1 will use the regular locking liquid called heparin. - Group 2 will use a new liquid called Kitelock. Both groups will use their locking liquid every day. They’ll also have check-ups, blood tests, and keep a daily diary. The study will last about 1 year and include 6 in-person visits and 10 phone or video visits.

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug). We want to know how well it works when it combined with either standard non-intensive (venetoclax + azacitidine) therapy or standard intensive (7+3) therapy for adults who have acute myeloid leukemia.

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug). We want to know how well this study drug works in people with AML that have certain mutations in the NPM1 gene and rearrangements involving the KMT2A gene when it is given alone or in combination with other cancer drugs.

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug) to be used in combination with an established dose of imatinib for people who have advanced gastrointestinal stromal tumors (GIST) and failed treatment with imatinib on its own.